Newsletter | October 15, 2020

10.15.20 -- Considerations For Transforming Clinical Trials

On The Future Of Psychiatric Disorders: Part 1 Of Transforming CNS Trials Series

The switch to remote methodologies as a response to COVID-19 has had a profound effect on the conduct of psychiatric disorder trials. Supporting these remote trials requires new tools, sophisticated technology, and, most importantly, deep scientific and clinical expertise. COVID-19 has forced everyone involved in psychiatric trials to reconsider not only the tools and technology they use, but the entire patient encounter.

On The Future Of Schizophrenia Trials: Part 2 Of Transforming CNS Trials Series

Remote assessments have become a necessity across central nervous system (CNS) trials, but some areas are more complicated than others. Schizophrenia provides one such example: The risk of variability is high, and sponsors are concerned. PANSS — the gold-standard rating scale for schizophrenia primary outcomes — is based largely on face-to-face interviews; it wasn’t developed for remote assessments. Is it still usable? The answer is addressed in this podcast.

Jeffrey Borghoff: Finding Joy And Purpose After An Early-Onset Alzheimer's Diagnosis

At 51, Jeffrey Borghoff was diagnosed with Alzheimer’s disease. What would devastate many people turned Borghoff into an advocate. The former software architect and developer is now a national spokesperson for the Alzheimer's Association and board member of the Greater New Jersey chapter. In this podcast, he talks about how the diagnosis forced him to reprioritize his life and become a champion for research funding and clinical trial participation.

Striving For Reliability: Optimizing Patient-Reported Data Through World-Class Design Management

Can patients be trained to report their symptoms more accurately? With proper design and implementation you can structure clinical trials so that patients learn how to better report their symptoms. During COVID-19 sponsors have had the opportunity to examine ways to introduce new technologies, such as telehealth, to clinical trial operations and to use more science-based tools for evaluating the performance of clinical trials.